The Intercepting Blood Cancers Meeting (IBC) 2023 will provide a unique, interactive platform for presentations on key clinical trial data and expert clinical insights for early interventions in blood cancers and how this impacts outcomes for patients; three key topic tracks will include:

• Monoclonal B lymphocytosis (MBL), chronic lymphocytic leukemia (CLL) and low-grade lymphoma
• Myelodysplastic syndromes (MDS) and clonal hematopoiesis of indeterminate potential (CHIP)
• Multiple myeloma (MM), smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS)

• Describe current knowledge of blood cancer precursors and how these might enable early clinical intervention
• Discuss ongoing clinical studies and any available data from these on treatment interceptions for early-stage blood cancers
• Share knowledge and clinical insights between blood cancer disciplines and therapy areas
• Plan for publication and dissemination of consensus findings from discussions across each of the key topic tracks